SRZN Stock Price, Chart, Stats & News
Surrozen Inc (SRZN) does not currently pay a dividend.
SRZN chart
Fundamentals
Gross margin | 84.56% |
Operating margin | -1210.58% |
Pretax margin | -6960.77% |
Net margin | -6960.77% |
Effective tax rate | – |
ROA | -245.15% |
ROE | 610.83% |
D/E | -0.04x |
Interest coverage ratio | – |
SRZN valuation
P/E | – |
P/S | 62.15x |
P/B | -1.15x |
P/CF | -7.15x |
P/FCF | -7.12x |
P/OCF | -7.15x |
PEG | 0.01x |
EV multiple | -2.92x |
About
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases.
Similar securities
Based on sector and market capitalization
